| CPC A61K 35/747 (2013.01) [A61K 8/99 (2013.01); A61P 17/06 (2018.01); A61P 17/10 (2018.01); A61P 17/12 (2018.01); A61K 2035/115 (2013.01)] | 16 Claims |
|
1. A method of treating or preventing an inflammatory dermatological disease, an allergic skin disease, or dysbiosis of epidermis or dysbiosis of cutaneous microbiota in a human in need thereof, the method comprising topically administering a therapeutically effective amount of a composition comprising a postbiotic second fermented supernatant of a Lactobacillus species selected from the group consisting of Lactobacillus casei and Lactobacillus paracasei, wherein the postbiotic second fermented supernatant is produced by a method comprising:
(i) fermenting a first culture of Lactobacillus casei or Lactobacillus paracasei to form a bacterial suspension comprising a first biomass of the Lactobacillus casei or the Lactobacillus paracasei and a first fermented supernatant;
(ii) separating the Lactobacillus casei or the Lactobacillus paracasei first biomass from the first fermented supernatant;
(iii) fermenting the Lactobacillus casei or the Lactobacillus paracasei biomass from step (in a minimum solution consisting of water, saline, phosphate buffer and a lactate salt to form a further fermented biomass comprising the Lactobacillus casei or the Lactobacillus paracasei and a second fermented supernatant; and
(iv) separating the Lactobacillus casei or the Lactobacillus paracasei from the further fermented biomass from step (iii) to obtain the postbiotic second fermented supernatant;
wherein the Lactobacillus casei or the Lactobacillus paracasei comprises in its DNA genome a DNA sequence 100% identical to one of the sequences selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 5.
|